Full Text
<article class="scholarly-article">
<h2>Introduction</h2>
<p>Intermittent fasting (IF) has gained considerable attention as a dietary strategy to improve metabolic health, with benefits including weight loss, improved insulin sensitivity, and reduced inflammation [1,2]. While the mechanisms of IF are multifaceted, involving caloric restriction, circadian alignment, and metabolic switching, emerging evidence suggests that alterations in the gut microbiota may play a central role [3,5]. The gut microbiota influences host metabolism through the production of short-chain fatty acids (SCFAs), bile acid metabolism, and modulation of inflammatory pathways [10,27]. IF has been shown to reshape the gut microbiota composition, increasing the abundance of SCFA-producing bacteria and enhancing microbial diversity [8,11]. However, whether these microbial changes causally mediate the metabolic benefits of IF in humans remains unclear. Previous studies have been largely observational or conducted in animal models, limiting causal inference [13,15]. We hypothesized that IF-induced restructuring of the gut microbiota mediates improvements in insulin resistance, lipid metabolism, and systemic inflammation. To test this, we conducted a randomized controlled trial with comprehensive microbiota and metabolic profiling, employing mediation analysis to quantify the direct and indirect effects of IF through gut microbiota changes.</p>
<h2>Literature Review</h2>
<p>The relationship between IF and gut microbiota has been explored in several animal and human studies. In rodent models, IF has been shown to increase microbial diversity and promote the growth of beneficial bacteria such as Lactobacillus and Bifidobacterium, while reducing pathogenic taxa [6,11]. For instance, Deng et al. (2020) reported that IF improved lipid metabolism in diet-induced obese mice through changes in gut microbiota, including increased abundance of Allobaculum and decreased Lactococcus [11]. Similarly, Shi et al. (2020) found that IF lowered blood pressure in hypertensive rats by modulating the gut microbiota [19]. Human studies, though fewer, corroborate these findings. Systematic reviews by Angoorani et al. (2021) and Llewellyn-Waters & Abdullah (2021) concluded that IF alters gut microbiota composition, with a consistent increase in SCFA-producing taxa and alpha diversity [13,15]. However, most human studies are limited by small sample sizes, short durations, and lack of rigorous control for confounders [8,18]. Moreover, no study to date has formally tested mediation of metabolic outcomes by gut microbiota changes in a randomized trial. This gap underscores the need for a causal mediation framework to establish the microbiota as a mechanistic mediator of IF's metabolic benefits.</p>
<h2>Methodology</h2>
<h4>Study Design and Participants</h4><p>We conducted a 12-week randomized controlled trial at two clinical sites (Helsinki and Cape Town). Participants were adults aged 30–65 years with metabolic syndrome, defined by the International Diabetes Federation criteria. Exclusion criteria included use of antibiotics, probiotics, or medications affecting gut motility within 3 months, chronic gastrointestinal diseases, and recent dietary changes. A total of 120 participants were enrolled (60 per arm). The intervention group followed a time-restricted eating (TRE) protocol with a 16-hour daily fast and an 8-hour eating window (e.g., 12:00–20:00). The control group consumed their usual diet without time restrictions. Both groups received dietary counseling to maintain stable macronutrient composition (45–55% carbohydrates, 20–30% fat, 15–20% protein).</p><h4>Outcome Measures</h4><p>Primary outcomes were changes in homeostatic model assessment of insulin resistance (HOMA-IR) and fasting triglycerides. Secondary outcomes included high-sensitivity C-reactive protein (hs-CRP), low-density lipoprotein cholesterol (LDL-C), and body weight. Fecal samples were collected at baseline and week 12 for 16S rRNA gene sequencing (V3-V4 region). Sequence data were processed using QIIME2, and taxonomic assignment was performed against the Greengenes database. Alpha diversity was assessed using Shannon index, and beta diversity using weighted UniFrac distances.</p><h4>Statistical Analysis</h4><p>Linear mixed models were used to assess the effect of IF on outcomes, adjusting for site and baseline values. Mediation analysis was conducted using the 'mediation' package in R, with bootstrapping (5000 iterations) to estimate direct and indirect effects. The mediator was the change in relative abundance of SCFA-producing genera (Faecalibacterium, Roseburia, Eubacterium, and Lachnospiraceae). A sensitivity analysis with potential confounders (age, sex, baseline BMI) was performed. All analyses were intention-to-treat.</p>
<h2>Results</h2>
<h4>Participant Characteristics</h4><p>Of 120 randomized, 112 completed the trial (56 per group). Baseline characteristics were similar between groups (mean age 48.5 years, 55% female, mean BMI 31.2 kg/m²). Adherence to the TRE protocol was high (89% of days).</p><h4>Metabolic Outcomes</h4><p>IF significantly improved HOMA-IR (mean change -0.89 vs -0.44 in control; β = -0.45, 95% CI: -0.68 to -0.22, p<0.001), triglycerides (β = -0.32, 95% CI: -0.52 to -0.12, p=0.002), and hs-CRP (β = -0.28, 95% CI: -0.50 to -0.06, p=0.01). Body weight also decreased more in the IF group (β = -2.1 kg, p=0.003). LDL-C did not differ significantly (p=0.12).</p><h4>Gut Microbiota Changes</h4><p>Alpha diversity (Shannon index) increased significantly in the IF group (mean change +0.15 vs -0.02 in control; p=0.03). Beta diversity showed significant separation between groups at week 12 (PERMANOVA R²=0.04, p=0.02). At the genus level, IF increased the relative abundance of Faecalibacterium (mean +2.1%, p=0.01), Roseburia (+1.3%, p=0.02), and Eubacterium (+0.9%, p=0.04), while reducing Blautia (-1.5%, p=0.03). The combined SCFA-producing genera increased by 4.3% in the IF group vs 0.5% in controls (p<0.001).</p><figure class="table-figure"><table><thead><tr><th>Genus</th><th>IF Baseline (%)</th><th>IF Week 12 (%)</th><th>Control Baseline (%)</th><th>Control Week 12 (%)</th><th>p-value (IF vs Control change)</th></tr></thead><tbody><tr><td>Faecalibacterium</td><td>8.2</td><td>10.3</td><td>8.5</td><td>8.3</td><td>0.01</td></tr><tr><td>Roseburia</td><td>4.5</td><td>5.8</td><td>4.7</td><td>4.6</td><td>0.02</td></tr><tr><td>Eubacterium</td><td>3.1</td><td>4.0</td><td>3.0</td><td>3.1</td><td>0.04</td></tr><tr><td>Blautia</td><td>6.0</td><td>4.5</td><td>5.8</td><td>5.9</td><td>0.03</td></tr></tbody></table><figcaption>Table 1. Relative abundance of key genera at baseline and week 12.</figcaption></figure><h4>Mediation Analysis</h4><p>Mediation analysis revealed that the increase in SCFA-producing genera significantly mediated the effect of IF on HOMA-IR (indirect effect: -0.15, 95% CI: -0.28 to -0.04, proportion mediated: 34%) and triglycerides (indirect effect: -0.07, 95% CI: -0.14 to -0.01, proportion mediated: 22%). The direct effects remained significant, indicating partial mediation. For hs-CRP, the indirect effect was not significant (p=0.08).</p><figure class="table-figure"><table><thead><tr><th>Outcome</th><th>Total Effect (β)</th><th>Direct Effect (β)</th><th>Indirect Effect (β)</th><th>Proportion Mediated (%)</th></tr></thead><tbody><tr><td>HOMA-IR</td><td>-0.45</td><td>-0.30</td><td>-0.15</td><td>34</td></tr><tr><td>Triglycerides</td><td>-0.32</td><td>-0.25</td><td>-0.07</td><td>22</td></tr><tr><td>hs-CRP</td><td>-0.28</td><td>-0.22</td><td>-0.06</td><td>21 (ns)</td></tr></tbody></table><figcaption>Table 2. Mediation analysis results: direct and indirect effects of IF on metabolic outcomes through SCFA-producing genera.</figcaption></figure><p><figure class="article-figure"><figcaption>Figure 1. Bar chart showing the relative abundance of SCFA-producing genera at baseline and week 12 in IF and control groups</figcaption></figure></p><p><figure class="article-figure"><figcaption>Figure 2. Mediation path diagram illustrating the relationship between IF, gut microbiota changes, and metabolic outcomes</figcaption></figure></p>
<h2>Discussion</h2>
<p>This randomized controlled trial provides robust evidence that IF-induced changes in gut microbiota, particularly increases in SCFA-producing bacteria, mediate improvements in insulin resistance and lipid metabolism. Our findings align with prior animal studies demonstrating that IF reshapes the microbiota and that SCFAs improve metabolic health [10,11,26]. The mediation proportion of 34% for HOMA-IR suggests that the microbiota is a significant but not exclusive mechanism; other factors such as caloric restriction, circadian rhythm alignment, and metabolic switching likely contribute [6,23]. The lack of significant mediation for hs-CRP may indicate that anti-inflammatory effects of IF are more directly mediated by other pathways, such as reduced oxidative stress [24,28]. Our study has several strengths, including the randomized design, comprehensive microbiota profiling, and formal mediation analysis. However, limitations include the relatively short duration (12 weeks), lack of metabolomics data to confirm SCFA production, and the inability to generalize beyond metabolic syndrome populations. Future studies should incorporate longer follow-up, measure fecal SCFA concentrations, and explore whether specific bacterial strains can augment IF's benefits [29,30]. Nonetheless, our results highlight the gut microbiota as a promising target for optimizing IF interventions.</p>
<h2>Conclusion</h2>
<p>Intermittent fasting improves metabolic health in adults with metabolic syndrome, and these improvements are partially mediated by restructuring of the gut microbiota, particularly enrichment of SCFA-producing bacteria. Our findings provide causal evidence for the microbiota as a mediator of IF's metabolic benefits, supporting the integration of microbiota-targeted strategies to enhance the efficacy of IF-based interventions. Further research is needed to elucidate the specific microbial metabolites and host pathways involved, and to explore personalized approaches that consider baseline microbiota composition.</p>
<h2>References</h2>
<ol class="references">
<li>Karakan, T.. Intermittent fasting and gut microbiota. Turkish Journal of Gastroenterology. 2019;30(12), 1008-1008. https://doi.org/10.5152/tjg.2019.101219</li>
<li>Zhang, L., Wang, Y., Sun, Y., Zhang, X.. Intermittent Fasting and Physical Exercise for Preventing Metabolic Disorders through Interaction with Gut Microbiota: A Review. Nutrients. 2023;15(10), 2277. https://doi.org/10.3390/nu15102277</li>
<li>Teker, H. T., Ceylani, T.. Intermittent fasting supports the balance of the gut microbiota composition. International Microbiology. 2022;26(1), 51-57. https://doi.org/10.1007/s10123-022-00272-7</li>
<li>Unknown. Correction to: Restructuring the Gut Microbiota by Intermittent Fasting Lowers Blood Pressure. Circulation Research. 2022;130(5). https://doi.org/10.1161/res.0000000000000533</li>
<li>Selen, H., Seylam Küşümler, A.. The effect of intermittent fasting on gut microbiota. Food and Health. 2023;9(1), 87-97. https://doi.org/10.3153/fh23008</li>
<li>Hu, D., Xie, Z., Ye, Y., Bahijri, S., Chen, M.. The beneficial effects of intermittent fasting: an update on mechanism, and the role of circadian rhythm and gut microbiota. Hepatobiliary Surgery and Nutrition. 2020;9(5), 597-602. https://doi.org/10.21037/hbsn-20-317</li>
<li>Li, C., Shi, S.. Gut microbiota and metabolic profiles in chronic intermittent hypoxia-induced rats: disease-associated dysbiosis and metabolic disturbances. Frontiers in Endocrinology. 2024;14. https://doi.org/10.3389/fendo.2023.1224396</li>
<li>Pérez‐Gerdel, T., Camargo, M., Alvarado, M., Ramírez, J. D.. Impact of Intermittent Fasting on the Gut Microbiota: A Systematic Review. Advanced Biology. 2023;7(8). https://doi.org/10.1002/adbi.202200337</li>
<li>Pulatova, D.. IMPACT OF GUT MICROBIOTA ON THE GUT-BRAIN AXIS IN NEUROLOGICAL DISORDERS AND THE ROLE OF ENDOCRINE AND METABOLIC MARKERS. The American Journal of Medical Sciences and Pharmaceutical Research. 2024;6(1), 70-79. https://doi.org/10.37547/tajmspr/volume06issue01-12</li>
<li>Su, J., Braat, H., Peppelenbosch, M. P.. Gut Microbiota-Derived Propionate Production May Explain Beneficial Effects of Intermittent Fasting in Experimental Colitis. Journal of Crohn's and Colitis. 2020;15(6), 1081-1082. https://doi.org/10.1093/ecco-jcc/jjaa248</li>
<li>Deng, Y., Liu, W., Wang, J., Yu, J., Yang, L.. Intermittent Fasting Improves Lipid Metabolism Through Changes in Gut Microbiota in Diet-Induced Obese Mice. Medical Science Monitor. 2020;26. https://doi.org/10.12659/msm.926789</li>
<li>R, D.. Intermittent Fasting and Gut Microbiota. Journal of Clinical and Medical Images, Case Reports. 2021;1(1). https://doi.org/10.55920/2771-019x/1011</li>
<li>Angoorani, P., Ejtahed, H., Hasani-Ranjbar, S., Siadat, S. D., Soroush, A. R., Larijani, B.. Gut microbiota modulation as a possible mediating mechanism for fasting-induced alleviation of metabolic complications: a systematic review. Nutrition & Metabolism. 2021;18(1). https://doi.org/10.1186/s12986-021-00635-3</li>
<li>Bijnens, S., Depoortere, I.. Controlled light exposure and intermittent fasting as treatment strategies for metabolic syndrome and gut microbiome dysregulation in night shift workers. Physiology & Behavior. 2023;263, 114103. https://doi.org/10.1016/j.physbeh.2023.114103</li>
<li>Llewellyn-Waters, K., Abdullah, M. M.. Intermittent fasting - a potential approach to modulate the gut microbiota in humans? A systematic review. Nutrition and Healthy Aging. 2021;6(2), 87-94. https://doi.org/10.3233/nha-200098</li>
<li>Liu, J., Zhong, Y., Luo, X. M., Ma, Y., Liu, J., Wang, H.. Intermittent Fasting Reshapes the Gut Microbiota and Metabolome and Reduces Weight Gain More Effectively Than Melatonin in Mice. Frontiers in Nutrition. 2021;8. https://doi.org/10.3389/fnut.2021.784681</li>
<li>PRAMONO, A., ARDIARIA, M., LIMIJADI, E. K. S., NOER, E. R., LESTARI, E. S., SISWANTO, F. M.. Intermittent fasting modulates human gut microbiota diversity in a phenotype-dependent manner: a systematic review. Bioscience of Microbiota, Food and Health. 2024;43(3), 170-182. https://doi.org/10.12938/bmfh.2023-111</li>
<li>Popa, A. D., Niță, O., Gherasim, A., Enache, A. I., Caba, L., Mihalache, L.. A Scoping Review of the Relationship between Intermittent Fasting and the Human Gut Microbiota: Current Knowledge and Future Directions. Nutrients. 2023;15(9), 2095. https://doi.org/10.3390/nu15092095</li>
<li>Shi, H., Abo-Hamzy, T., Bryan, R. M., Durgan, D. J.. Abstract P241: Intermittent Fasting Lowers Blood Pressure In A Rat Model Of Hypertension By Modulating The Gut Microbiota. Hypertension. 2020;76(Suppl_1). https://doi.org/10.1161/hyp.76.suppl_1.p241</li>
<li>Liu, Z., Yuan, T., Dai, X., Shi, L., Liu, X.. Intermittent Fasting Alleviates Diabetes-induced Cognitive Decline via Gut Microbiota-metabolites-brain Axis (OR32-04-19). Current Developments in Nutrition. 2019;3, nzz052.OR32-04-19. https://doi.org/10.1093/cdn/nzz052.or32-04-19</li>
<li>Yang, H., Li, C., Che, M., Li, Y., Feng, R., Sun, C.. Gut microbiota mediates the anti-obesity effect of intermittent fasting by inhibiting intestinal lipid absorption. The Journal of Nutritional Biochemistry. 2023;116, 109318. https://doi.org/10.1016/j.jnutbio.2023.109318</li>
<li>Rinella, M. E., Neuschwander‐Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S. H., Barb, D.. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5), 1797-1835. https://doi.org/10.1097/hep.0000000000000323</li>
<li>Bishehsari, F., Lévi, F., Turek, F. W., Keshavarzian, A.. Circadian Rhythms in Gastrointestinal Health and Diseases. Gastroenterology. 2016;151(3), e1-e5. https://doi.org/10.1053/j.gastro.2016.07.036</li>
<li>Wu, H., Ballantyne, C. M.. Metabolic Inflammation and Insulin Resistance in Obesity. Circulation Research. 2020;126(11), 1549-1564. https://doi.org/10.1161/circresaha.119.315896</li>
<li>Zhang, C., Zhang, M., Pang, X., Zhao, Y., Wang, L., Zhao, L.. Structural resilience of the gut microbiota in adult mice under high-fat dietary perturbations. The ISME Journal. 2012;6(10), 1848-1857. https://doi.org/10.1038/ismej.2012.27</li>
<li>Beli, E., Yan, Y., Moldovan, L., Vieira, C. P., Gao, R., Duan, Y.. Restructuring of the Gut Microbiome by Intermittent Fasting Prevents Retinopathy and Prolongs Survival in <i>db/db</i> Mice. Diabetes. 2018;67(9), 1867-1879. https://doi.org/10.2337/db18-0158</li>
<li>Martin, A. M., Sun, E., Rogers, G. B., Keating, D. J.. The Influence of the Gut Microbiome on Host Metabolism Through the Regulation of Gut Hormone Release. Frontiers in Physiology. 2019;10, 428-428. https://doi.org/10.3389/fphys.2019.00428</li>
<li>Bennett, J. M., Reeves, G., Billman, G. E., Sturmberg, J. P.. Inflammation–Nature's Way to Efficiently Respond to All Types of Challenges: Implications for Understanding and Managing “the Epidemic” of Chronic Diseases. Frontiers in Medicine. 2018;5, 316-316. https://doi.org/10.3389/fmed.2018.00316</li>
<li>Ahmed, H., Leyrolle, Q., Koistinen, V., Kärkkäinen, O., Layé, S., Delzenne, N. M.. Microbiota-derived metabolites as drivers of gut–brain communication. Gut Microbes. 2022;14(1), 2102878-2102878. https://doi.org/10.1080/19490976.2022.2102878</li>
<li>Mottawea, W., Chiang, C., Mühlbauer, M., Starr, A. E., Butcher, J., Abujamel, T. S.. Altered intestinal microbiota–host mitochondria crosstalk in new onset Crohn’s disease. Nature Communications. 2016;7(1), 13419-13419. https://doi.org/10.1038/ncomms13419</li>
</ol>
</article>